

A. CLASSIFICATION OF SUBJECT MATTER

G01N33/50 C12Q1/68 A61K39/395 A61K48/00 C07K14/705  
C07K14/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

G01N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, Sequence Search, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97/28149 A (MERCK & CO., INC; LEIBOWITZ, MARK, D; BERGER, JOEL, P; MOLLER, DAVID,) 7 August 1997 (1997-08-07) p. 4, line 28 - p. 9, line 5, Examples 1B, 3B and 6	1-11, 19, 21-26
X	US 2003/224514 A1 (GAARDE WILLIAM ET AL) 4 December 2003 (2003-12-04)	20-22
A	paragraphs [0008]-[0012], [0021] - [0024], Examples 10, 13 - 16, claims 1 - 11	1-17, 23-26
	----- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

8 July 2005

Date of mailing of the international search report

28. 11. 2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Hoesel, H

ISA/210 (second sheet) (January 2004)

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>GUPTA R A ET AL: "Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 24, 21 November 2000 (2000-11-21), pages 13275-13280, XP002972848 ISSN: 0027-8424 the whole document -----</p>	1-26

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2005/002529

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 26 with respect to IA  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claim 32 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-18, 24-26 (part.); 19-23

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-18, 24-26 (part.); 19-23

Use of PPARD gene/protein as screening marker/diagnostic marker/therapeutical target in conjunction with cardiovascular diseases  
---

2. claims: 1-18, 24-26 (part.)

Use of PPARD gene/protein as screening marker/diagnostic marker/therapeutical target in conjunction with infections  
---

3. claims: 1-18, 24-26 (part.)

Use of PPARD gene/protein as screening marker/diagnostic marker/therapeutical target in conjunction with cancer  
---

4. claims: 1-18, 24-26 (part.)

Use of PPARD gene/protein as screening marker/diagnostic marker/therapeutical target in conjunction with gastrointestinal diseases (ileum inflammation, liver liver cirrhosis, liver lupus disease)  
---

5. claims: 1-18, 24-26 (part.)

Use of PPARD gene/protein as screening marker/diagnostic marker/therapeutical target in conjunction with hematological diseases (spleen liver cirrhosis)  
---

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9728149	A	07-08-1997	AU	1856997 A		22-08-1997
US 2003224514	A1	04-12-2003	US	2004063129 A1		01-04-2004